" class="no-js "lang="en-US"> Bristol Myers Squibb - Medtech Alert
Wednesday, May 31, 2023
Bristol Myers Squibb | Pharmtech Focus

Bristol Myers Squibb

About Bristol Myers Squibb

Bristol Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. Our medicines are helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, fibrosis and others. We have built a sustainable pipeline of potential therapies, and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient at the right time to achieve the best outcome.

Through the Bristol-Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people. Each day, our employees around the world work together for patients – it drives everything we do.

Related Story

Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients

April 20 2023

Tubulis and Bristol Myers Squibb today announced that they have entered into a strategic license […]

Foundation Medicine and Bristol Myers Squibb Expand Partnership to Focus on Companion Diagnostic Development

April 11 2023

Foundation Medicine, a pioneer in molecular profiling for cancer announced today, an expanded collaboration with […]

PathAI Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb

August 26 2022

PathAI, a global leader in AI-powered pathology, today announced a multi-year expanded collaboration agreement with Bristol Myers Squibb. […]

GentiBio Announces Collaboration with Bristol Myers Squibb to Pioneer Engineered Treg Therapies for Inflammatory Bowel Diseases

August 10 2022

GentiBio, Inc., an engineered regulatory T cells (Tregs) company,  announced today that it has entered […]

Breakthrough Treatment to Boost Life Chances for Hundreds of People With Respiratory Cancer

July 18 2022

The first new mesothelioma treatment to be approved in nearly 15 years will be made […]

Roche Announces Collaboration With Bristol Myers Squibb to Advance Personalised Healthcare Through Digital Pathology Solutions

March 25 2022

Roche (SIX: RO, ROG;OTCQX: RHHBY) today announced that it has entered into a collaboration with Bristol […]

Transcenta Announces Global Clinical Collaboration with Bristol Myers Squibb to Evaluate TST001 in Combination with Opdivo® in Patients with Locally Advanced or Metastatic Gastric / Gastroesophageal Junction Cancer

March 22 2022

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in […]

Compugen Announces Collaboration Expansion with Bristol Myers Squibb Alongside $20 Million Equity Investment

November 11 2021

Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced today […]

Bristol Myers Squibb Receives Positive CHMP Opinion for Zeposia (ozanimod) as a Treatment for Adult Patients with Moderately to Severely Active Ulcerative Colitis

October 15 2021

Bristol Myers Squibb (NYSE:BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of […]